Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy (ALPHAGEM)

Clinical Trials, contributed by Howard A. Young
Clinical Trials, contributed by Howard A. Young

ClinicalTrials.gov ID NCT05941845
Sponsor Centre Hospitalier Universitaire de Nice
Information provided by Centre Hospitalier Universitaire de Nice (Responsible Party)

Study Overview – Brief Summary

Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies. Current management is based on the use of immunosuppressive therapies. MN patients with a pro-inflammatory Th17 cytokine profile have a 10.5-fold increased risk of disease relapse. Interferon-based immunomodulatory therapies are effective in blocking the production of cytokines in the Th17 pathway avoiding an increased risk of infection, unlike immunosuppressive treatments. To date, these treatments have not been evaluated in the management of MN. The aims of the ALPHAGEM project are to monitor the immunological activity of the disease before and after 6 months of personalized interferon-alfa treatment in MN patients.